Atea Pharmaceuticals (AVIR) vs Inovio Pharmaceuticals (INO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Atea Pharmaceuticals (AVIR) has outperformed Inovio Pharmaceuticals (INO) over the past year, gaining 33.3% versus a gain of 0.0%. Over five years, AVIR leads with a -51.4% price change compared with -98.0% for INO. Inovio Pharmaceuticals is the larger company by market cap ($329.7 million vs $318.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AVIR | INO |
|---|---|---|
| Share price | $3.96 | $1.76 |
| Market cap | $318.00M | $329.66M |
| 1-day change | +0.76% | +2.92% |
| YTD return | +10.92% | +1.15% |
| 1-year return | +33.33% | 0.00% |
| 5-year return | -51.35% | -97.98% |
| EPS (TTM) | $-1.95 | $-0.59 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $65.34K |
| Revenue growth (YoY) | — | -69.99% |
| Net income (latest FY) | $-158.35M | $-84.95M |
| Operating margin | — | -132871.32% |
| Net margin | — | -130000.00% |
| 52-week high | $6.45 | $2.72 |
| 52-week low | $2.96 | $0.56 |
| Distance from 52-week high | -38.60% | -35.29% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +127.27% | +259.66% |
| Average volume | 290.60K | 11.24M |
| Shares outstanding | 80.30M | 187.31M |
| Employees | 55 | 112 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AVIR has outperformed INO by 33.3 percentage points over the past year.
About Atea Pharmaceuticals
AVIR stock →Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV).
Health Care · Biotechnology: Pharmaceutical Preparations · 55 employees
About Inovio Pharmaceuticals
INO stock →Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses SynCon, to help engineer precisely designed plasmid DNA plasmids, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.
Health Care · Biotechnology: Pharmaceutical Preparations · 112 employees
AVIR vs INO FAQ
Which is bigger, Atea Pharmaceuticals or Inovio Pharmaceuticals?
Inovio Pharmaceuticals (INO) is larger, with a market capitalization of $329.66M compared with $318.00M for Atea Pharmaceuticals (AVIR).
Which stock has performed better over the past year, AVIR or INO?
AVIR returned +33.33% over the past 12 months, compared with 0.00% for INO (price return, excluding dividends). Past performance does not predict future results.
Are Atea Pharmaceuticals and Inovio Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.